Health-related quality of life (HRQoL) in idiopathic inflammatory myopathy: A systematic review

PLoS ONE

Volumn 11, Issue 8, 2016, Pages

  Leclair, Valérie ^a   Regardt, Malin ^b,c   Wojcik, Sophie ^a   Hudson, Marie ^a,d,e   Baron, M ^f   Genge, A ^f   O'Ferrall, E ^f   Vinet, E ^f   Gyger, G ^f   Fortin, P R ^f   Fritzler, M ^f  

^a MCGILL UNIVERSITY   (Canada)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^c KAROLINSKA INSTITUTE   (Sweden)

^d MCGILL UNIVERSITY   (Canada)

^e MCGILL UNIVERSITY   (Canada)

^f NONE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CHRONIC DISEASE; CLINICAL FEATURE; DISEASE ACTIVITY; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE DURATION; HUMAN; INFORMATION PROCESSING; MOOD; MYOSITIS; QUALITY OF LIFE; SYSTEMATIC REVIEW; HEALTH STATUS;

HEALTH STATUS; HUMANS; MYOSITIS; QUALITY OF LIFE;

EID: 84983039666     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0160753     Document Type: Article

References (28)

1. Oddis CV, Rider LG, Reed AM, Ruperto N, Brunner HI, Koneru B, et al. International consensus guidelines for trials of therapies in the idiopathic inflammatory myopathies. Arthritis Rheum 2005; 52:2607-15. PMID: 16142757
2. Bohan A, Peter JB. Polymyositis and dermatomyositis (second of 2 parts). N Engl J Med 1975; 292:403-7. PMID: 1089199
3. Bohan A, Peter JB. Polymyositis and dermatomyositis (first of 2 parts). N Engl J Med 1975; 292:344-7. PMID: 1090839
4. Sontheimer RD. Would a new name hasten the acceptance of amyopathic dermatomyositis (dermatomyositis siné myositis) as a distinctive subset within the idiopathic imflammatory myopahies spectrum of clinical illness? J Am Acad Dermatol 2002; 46:626-36. PMID: 11907524
5. Hoogendijk JE, Amato AA, Lecky BR, Choy EH, Lundberg IE, Rose MR, et al. 119th ENMC international workshop: trial design in adult idiopathic inflammatory myopathies, with the exception of inclusion body myositis, 10-12 October 2003, Naarden, The Netherlands. Neuromuscular disorders: NMD. 2004; 14:337-45. PMID: 15099594
6. Griggs RC, Askanas V, DiMauro S, Engel A, Karpati G, Mendell JR, et al. Inclusion body myositis and myopathies. Ann Neurol 1995; 38:705-13. PMID: 7486861
7. The World Health Organization Quality of Life Assessment (WHOQOL): development and general psychometric properties. Social science & medicine 1998; 46:1569-85.
8. Graham CD, Rose MR, Grunfeld EA, Kyle SD, Weinman J. A systematic review of quality of life in adults with muscle disease. J Neurol 2011; 258:1581-92. doi: 10.1007/s00415-011-6062-5 PMID: 21597956
9. Rider LG, Werth VP, Huber AM, Alexanderson H, Rao AP, Ruperto N, et al. Measures of adult and juvenile dermatomyositis, polymyositis, and inclusion body myositis: Physician and Patient/Parent Global Activity, Manual Muscle Testing (MMT), Health Assessment Questionnaire (HAQ)/Childhood Health Assessment Questionnaire (C-HAQ), Childhood Myositis Assessment Scale (CMAS), Myositis Disease Activity Assessment Tool (MDAAT), Disease Activity Score (DAS), Short Form 36 (SF-36), Child Health Questionnaire (CHQ), physician global damage, Myositis Damage Index (MDI), Quantitative Muscle Testing (QMT), Myositis Functional Index-2 (FI-2), Myositis Activities Profile (MAP), Inclusion Body Myositis Functional Rating Scale (IBMFRS), Cutaneous Dermatomyositis Disease Area and Severity Index (CDASI), Cutaneous Assessment Tool (CAT), Dermatomyositis Skin Severity Index (DSSI), Skindex, and Dermatology Life Quality Index (DLQI). Arthritis Care Res (Hoboken) 2011; 63: S118-57.
10. Bronner IM, Van Der Meulen MFG, De Visser M, Kalmijn S, Van Venrooij WJ, Voskuyl AE, et al. Long-term outcome in polymyositis and dermatomyositis. Ann Rheum Dis 2006; 65:1456-61. PMID: 16606652
11. Chung YL, Mitchell HL, Houssien DA, Al-Mahrouki H, Carr AJ, Scott DL. A comparative study of outcome in myositis and other musculoskeletal disorders assessed using the Nottingham health profile. Clin Exp Rheumatol 2001; 19:447-50. PMID: 11491502
12. Armadans-Tremolosa I, Selva-O'Callaghan A, Visauta-Vinacua B, Guilera G, Pinal-Fernandez I, Vilardell-Tarres M. Health-related quality of life and well-being in adults with idiopathic inflammatory myopathy. Clin Rheumatol 2014; 33:1119-25. doi: 10.1007/s10067-014-2685-0 PMID: 24894104
13. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gotzsche PC, Ioannidis JP, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ 2009; 339:b2700. doi: 10.1136/bmj.b2700 PMID: 19622552
14. Goreshi R, Chock M, Foering K, Feng R, Okawa J, Rose M, et al. Quality of life in dermatomyositis. J Am Acad Dermatol 2011; 65:1107-16. doi: 10.1016/j.jaad.2010.10.016 PMID: 21722989
15. Ponyi A, Borgulya G, Constantin T, Vancsa A, Gergely L, Danko K. Functional outcome and quality of life in adult patients with idiopathic inflammatory myositis. Rheumatology 2005; 44:83-8. PMID: 15381789
16. Regardt M, Henriksson EW, Alexanderson H, Lundberg IE. Patients with polymyositis or dermatomyositis have reduced grip force and health-related quality of life in comparison with reference values: An observational study. Rheumatology 2011; 50:578-85. doi: 10.1093/rheumatology/keq356 PMID: 21097879
17. Rose MR, Sadjadi R, Weinman J, Akhtar T, Pandya S, Kissel JT, et al. Role of disease severity, illness perceptions, and mood on quality of life in muscle disease. Muscle Nerve 2012; 46:351-9. doi: 10.1002/mus.23320 PMID: 22907225
18. Sultan SM, Ioannou Y, Moss K, Isenberg DA. Outcome in patients with idiopathic inflammatory myositis: Morbidity and mortality. Rheumatology 2002; 41:22-6. PMID: 11792875
19. Guyatt GH, Oxman AD, Vist G, Kunz R, Brozek J, Alonso-Coello P, et al. GRADE guidelines: 4. Rating the quality of evidence-study limitations (risk of bias). J Clin Epidemiol 2011; 64:407-15. doi: 10.1016/j.jclinepi.2010.07.017 PMID: 21247734
20. Sadjadi R, Rose MR, Tawil R, Griggs R, Thornton C, Jackson C, et al. What determines quality of life in inclusion body myositis? J Neurol Neurosurg Psychiatry 2010; 81:1164-6. doi: 10.1136/jnnp.2009.183863 PMID: 20601666
21. Van De Vlekkert J, Hoogendijk JE, De Visser M. Long-term follow-up of 62 patients with myositis. J Neurol 2014; 261:992-8. PMID: 24658663
22. Sterne JAC, Higgins JPT, Reeves B on behalf of the development group for ACROBAT-NRSI. A Cochrane Risk of Bias Assessment Tool: for Non-Randomized Studies of Interventions (ACROBAT-NRSI), Version 1.0.0. 24 September 2014. Available: http://www.riskofbias.info. Accessed August 2015.
23. Jackson CE, Barohn RJ, Gronseth G, Tawil R, Griggs R, Thornton C, et al. Inclusion body myositis functional rating scale: A reliable and valid measure of disease severity. Muscle Nerve 2008; 37:473-6. doi: 10.1002/mus.20958 PMID: 18236463
24. The Muscle Study Group, Randomized pilot trial of high-dose βINF-1a in patients with inclusion body myositis. Neurology 2004; 63:718-20. PMID: 15326251
25. Marie I, Hatron PY, Dominique S, Cherin P, Mouthon L, Menard JF. Short-term and long-term outcomes of interstitial lung disease in polymyositis and dermatomyositis: a series of 107 patients. Arthritis Rheum 2011; 63:3439-47. doi: 10.1002/art.30513 PMID: 21702020
26. Youssof S. The relationship between physical symptoms and health-related quality of life in oculopharyngeal muscular dystrophy. Muscle Nerve, 2015 (Epub ahead of printing).
27. van der Meulen MF, Bronner IM, Hoogendijk JE, Burger H, van Venrooij WJ, Voskuyl AE, et al. Polymyositis: an overdiagnosed entity. Neurology 2003; 61:316-21. PMID: 12913190
28. Shu XM, Lu X, Xie Y, Wang GC. Clinical characteristics and favorable long-term outcomes for patients with idiopathic inflammatory myopathies: a retrospective single center study in China. BMC Neurol 2011; 11:143. doi: 10.1186/1471-2377-11-143 PMID: 22070623